Donepezil provides positive effects to patients treated with gabapentin for neuropathic pain: an exploratory study

• Published in: Acta anaesthesiologica Scandinavica 2014-01, Vol.58 (1), p.61-73
• Main Authors: BASNET, A., BUTLER, S., HONORÉ, P. H., BUTLER, M., GORDH, T. E., KRISTENSEN, K., BJERRUM, O. J.
• Format: Article
• Language: English
• Subjects: Acetylcholinesterase; Adult; Aged; Algorithms; Amines - adverse effects; Amines - therapeutic use; Analgesics - adverse effects; Analgesics - therapeutic use; Cyclohexanecarboxylic Acids - adverse effects; Cyclohexanecarboxylic Acids - therapeutic use; Cyclohexanols - therapeutic use; Drug Therapy, Combination; Female; gamma-Aminobutyric Acid - adverse effects; gamma-Aminobutyric Acid - therapeutic use; Humans; Indans - adverse effects; Indans - therapeutic use; Male; Middle Aged; Neuralgia - drug therapy; Neuroprotective Agents - adverse effects; Neuroprotective Agents - therapeutic use; Pain management; Pain Measurement - drug effects; Piperidines - adverse effects; Piperidines - therapeutic use; Quality of Life; Sample Size; Venlafaxine Hydrochloride
• ISSN: 0001-5172; 1399-6576; 1399-6576
• DOI: 10.1111/aas.12218

Background The first‐line medication gabapentin and the acetylcholinesterase inhibitor donepezil represent a new promising combination to improve treatment outcomes for patients with severe neuropathic pain. The drugs have previously shown synergism following co‐administration in nerve‐injured rats. Methods The clinical relevance of adding donepezil to existing gabapentin treatment in patients with post‐traumatic neuropathic pain was explored in this open‐label study. The study comprised two consecutive periods of minimum 6 weeks: (1) titration of gabapentin to the highest tolerable dose or maximum 2400 mg daily, and (2) addition of donepezil 5 mg once daily to the fixed gabapentin dose. Efficacy and tolerability were assessed by ratings of pain intensity, questionnaires for pain and health‐related quality of life, and reporting of adverse events. Pain scores were also analysed using mixed‐effects analysis with the software NONMEM to account for intersubject variability. Results Eight patients commenced treatment with donepezil, of which two withdrew because of adverse events. Addition of donepezil resulted in clinically relevant reductions of pain (> 11 units on a 0–100 scale) and improved mental wellness in three of six patients. The remaining three patients had no obvious supplemental effect. Mixed‐effects analysis revealed that pain scores were significantly lower during co‐administration (P